The US Food and Drug Administration (FDA) has approved an improved stool collection kit of Geneoscopy’s RNA-based colorectal cancer (CRC) screening test, ColoSense. The new kit enhances user ...
Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
Pairing diagnostic innovation with improved patient experience, ColoSense aims to streamline the screening process and increase compliance Geneoscopy, Inc., a life sciences company focused on ...
The detection of microRNA (miRNA) dysregulation in stool is a novel approach for the diagnosis of colorectal carcinoma (CRC). The aim of this study is to investigate the use of miR-221 and miR-18a in ...
Geneoscopy’s New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
ST. LOUIS, July 24, 2025--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, received FDA approval to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback